HNN3.0

Project cooperationUpdated on 22 January 2026

Allogeneic Cell therapy of cancer an autoimmune diseases

Principal Investigator at IRCCS Azienda Ospedaliera Metropolitana, plesso Ospedale Policlinico San Martino

Genova, Italy

About

-Development and validation of off-the-shelf cell therapies

-Multi-omics data available for deep characterization and identification of target gene to implement safety and efficacy

-Standardization of manufacturing

-Pre-clinical and clinical grade manufacturing

-In vitro and in vivo models

-expertise in cancer vaccines and their combination with other therapies

-genomic profile of cancer stem cells and their susceptibility to cell therapy

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Similar opportunities